Physician profile
Siamak Arassi
NPI 1083680417
$1,675.06
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $430 · 2021: $551 · 2022: $267.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $440.46 | 2020-2022 | |
| Gilead Sciences, INC. | $321.37 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $229.04 | 2019-2021 | |
| Allergan, INC. | $170.28 | 2019-2020 | |
| Ucb, INC. | $153.44 | 2019-2021 | |
| Indivior INC. | $81.15 | 2019-2022 | |
| Mdd US Operations, LLC | $71.19 | 2019-2020 | |
| Alkermes, INC. | $52.13 | 2019-2020 | |
| Shire North American Group INC | $49.67 | 2019 | |
| Uswm, LLC | $47.07 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $32.71 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.55 | 2019-2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siamak Arassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.